How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/nonvalvular-atrial-fibrillation.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Nonvalvular atrial fibrillation — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nonvalvular atrial fibrillation (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Nonvalvular atrial fibrillation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Xarelto	rivaroxaban	Johnson & Johnson	Direct Factor Xa Inhibitor	Factor Xa (FXa)		2011-01-01
Xarelto	Xarelto	University Hospital, Montpellier		Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Johnson & Johnson · 1 drug in Nonvalvular atrial fibrillation
University Hospital, Montpellier · 1 drug in Nonvalvular atrial fibrillation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Nonvalvular atrial fibrillation:

Cite this brief

Drug Landscape (2026). Nonvalvular atrial fibrillation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/nonvalvular-atrial-fibrillation. Accessed 2026-06-10.

Nonvalvular atrial fibrillation full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing